Online inquiry

IVTScrip™ mRNA-Anti-NOTCH2&NOTCH3, OMP-59R5(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12782MR)

This product GTTS-WQ12782MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets NOTCH2&NOTCH3 gene. The antibody can be applied in Pancreatic Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001200001.2; NM_000435.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4853; 4854
UniProt ID Q04721; Q9UM47
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-NOTCH2&NOTCH3, OMP-59R5(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ12782MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ460MR IVTScrip™ mRNA-Anti-PDGFRA, 3G3(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA 3G3
GTTS-WQ1167MR IVTScrip™ mRNA-Anti-TNF, ABP 501(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABP 501
GTTS-WQ15528MR IVTScrip™ mRNA-Anti-TGM2, UCB-7858(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA UCB-7858
GTTS-WQ5617MR IVTScrip™ mRNA-Anti-KDR, CDP791(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CDP791
GTTS-WQ11192MR IVTScrip™ mRNA-Anti-TNFRSF4, MEDI0562(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MEDI0562
GTTS-WQ11899MR IVTScrip™ mRNA-Anti-CCR2, MLN-1202(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MLN-1202
GTTS-WQ6828MR IVTScrip™ mRNA-Anti-IL3RA, DT-IL-3(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA DT-IL-3
GTTS-WQ5849MR IVTScrip™ mRNA-Anti-CD40, CHIR-12,12(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CHIR-12,12
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.